glp 1 vs sglt2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Blood pressure effects of SGLT2
Description
At the same time, overall spending on GLP-1 drugs has grown substantially, with national pharmacy spend rising more than 500 % from 2018 to 2023, underscoring the economic impact on payers and employers alike
Pi-Sunyer X et al
Lowering the dose of GLP-1 receptor agonist or using a slower titration regimen may help to mitigate these effects
List prices are not necessarily net prices paid as manufacturers provide insurer rebates and patient coupons
Hennen, S
